Biodexa Pharmaceuticals (BDRX) has released an update.
Biodexa Pharmaceuticals has scheduled a General Meeting to propose resolutions aimed at reducing the par value of its ordinary shares, which will allow the company to issue shares above this value without altering the number of shares outstanding. This strategic move comes as the company continues to focus on developing its innovative pipeline targeting unmet medical needs, including treatments for cancer and diabetes.
For further insights into BDRX stock, check out TipRanks’ Stock Analysis page.
